Xeloda should also not be used in the following groups: • patients who have had severe and unexpected reactions to fluoropyrimidine therapy (a group of anticancer medicines); 2/ 3 • patients with dihydropyrimidine dehydrogenase deficiency (low levels of an enzyme); • pregnant or breast-feeding women; • patients with severe leucopenia, neutropenia, or thrombocytopenia (low levels of white cells or platelets in the blood); • patients with severe liver or kidney disease; • patients treated with sorivudine or similar anticancer medicines such as brivudine within the last four weeks.